ArticleJournal of experimental pharmacology2025
Gingerols and Shogaols of
Article in Journal of experimental pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Studies on the anticonvulsant potential of 6-gingerol, an active ingredient of ginger rhizome.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gingerols and shogaols are the main active constituents in Purpose: To elucidate the binding energy and stability of gingerols and shogaols toward human GABA Methods: The ligands, namely gingerols (6-, 8-, and 10-gingerol) and shogaols (6-, 8-, and 10-shogaol), were evaluated by pre-ADMET screening tools and molecular docking simulation towards hGABA Results: The best pre-ADMET prediction was shown by 6-gingerol, whereas the molecular docking simulations revealed that the best binding affinity and stability were shown by 6-gingerol (-7.41 kcal/mol) and 10-shogaol (-8.24 kcal/mol), which are comparable to that of diazepam. They build hydrogen bonds with α1 Ser206 and pi interaction with γ2 Phe77. The MD simulation confirmed that the stability of the 10-shogaol/hGABA Conclusion: 6-Gingerol and 10-shogaol of EEZO may have the potential to be developed as novel allosteric agonists of human GABA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.